Zanubrutinib versus Venetoclax-Obinutuzumab Fixed-Duration Therapy

Dr. Shadman transitions to discussing the second analysis comparing zanubrutinib as continuous therapy versus venetoclax-obinutuzumab fixed-duration regimen, the previously preferred approved fixed-duration option in the United States. This study compared SEQUOIA (zanubrutinib approval study) versus CLL14 (venetoclax-obinutuzumab approval study), using patient-level data from SEQUOIA against published CLL14 data, demonstrating 44% risk reduction for progression or death favoring zanubrutinib.

Dr. Brander emphasizes practical relevance for patients, noting that until recent acalabrutinib-venetoclax approval, main frontline discussions involved continuous BTK approaches versus venetoclax-obinutuzumab fixed-duration therapy. Initially, both treatments show similar progression-free survival during the first year, with differences emerging during longer follow-up as patients continue zanubrutinib continuously while venetoclax-obinutuzumab stops after 12 months.

Individual patient considerations become crucial, particularly for severe CLL consequences including autoimmune cytopenias or complications like effusions where sustained disease control proves advantageous. Dr. Brander highlights important methodological considerations including different trial timing and patient populations, with matching based on captured and reported variables rather than exact population replication. The analysis revealed differences by IGHV mutation status, with unmutated IGHV showing less favorable outcomes for time-limited therapy, consistent with longer CLL14 follow-up data indicating variable progression risk by disease markers and emphasizing patient treatment goals regarding disease control maintenance versus treatment-free periods.